19 July 2024
19 July 2024
Article doesn't exist
The Phase III trial evaluating Nubeqa in patients with metastatic hormone-sensitive prostate cancer met its primary endpoint.
The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.
hVIVO specialises in human challenge trials for influenza and RSV therapeutic candidates.
A decision by the US regulator under the Prescription Drug User Fee Act is anticipated by 15 January 2025.
The filing is based on findings from the Phase III MOTION clinical trial assessing the safety and efficacy of vimseltinib.
As part of the financing agreement, LongRiver Investments will join Rona's board.
Meitheal gains access to development and regulatory works, intellectual property rights, technology and related know-how.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
